Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported a small, routine option exercise and share sale. She exercised stock options to acquire 6,000 shares of common stock at $6.14 per share, then sold 6,000 shares in an open-market transaction at a weighted average price of $19.87 per share.

The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. After the sale, Townson directly holds 67,845 shares of common stock and 209,290 stock options following the derivative transaction.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares ($119,220)

Net Sell 3 txns

Insider Townson Sharon

Role Chief Scientific Officer

Sold 6,000 shs ($119K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,000	$0.00	--
Exercise	Common Stock	6,000	$6.14	$37K
Sale	Common Stock	6,000	$19.87	$119K

Holdings After Transaction: Stock Option (Right to Buy) — 209,290 shares (Direct, null); Common Stock — 73,845 shares (Direct, null)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $20.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option is fully vested and exercisable.

Key Figures

Shares sold: 6,000 shares Sale price: $19.87 per share Options exercised: 6,000 shares +3 more

6 metrics

Shares sold 6,000 shares Common stock sold in open-market transaction on May 29, 2026

Sale price $19.87 per share Weighted average price for 6,000 shares sold; trades from $19.74–$20.00

Options exercised 6,000 shares Common shares acquired via stock option exercise on May 29, 2026

Option exercise price $6.14 per share Conversion or exercise price for Stock Option (Right to Buy)

Shares held after sale 67,845 shares Direct common stock ownership following the reported transactions

Options remaining 209,290 options Stock Option (Right to Buy) position following the derivative transaction

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) listed as a derivative security with underlying common stock."

open-market sale financial

"transaction_action is described as an open-market sale for the 6,000 common shares."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/01/2026 - 04:06 PM Accepted by SEC EDGAR 06/01/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townson Sharon

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		M⁽¹⁾		6,000	A	$6.14	73,845	D
Common Stock	05/29/2026		S⁽¹⁾		6,000	D	$19.87⁽²⁾	67,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.14	05/29/2026		M⁽¹⁾			6,000	⁽³⁾	04/12/2031	Common Stock	6,000	$0	209,290	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $20.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. This option is fully vested and exercisable.

	/s/ Phil Nickson, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Monte Rosa Therapeutics (GLUE) report for Sharon Townson?

Monte Rosa Therapeutics reported that Chief Scientific Officer Sharon Townson exercised options for 6,000 shares at $6.14 and sold 6,000 common shares at a weighted average price of $19.87 on May 29, 2026, according to a Form 4 filing.

At what prices did Sharon Townson trade Monte Rosa Therapeutics (GLUE) stock?

Sharon Townson exercised stock options at an exercise price of $6.14 per share and sold 6,000 Monte Rosa Therapeutics common shares at a weighted average price of $19.87, with individual sale prices ranging from $19.74 to $20.00 per share.

How many Monte Rosa Therapeutics (GLUE) shares does Sharon Townson hold after the Form 4 transactions?

Following the reported transactions, Sharon Townson directly holds 67,845 shares of Monte Rosa Therapeutics common stock. The filing also shows 209,290 stock options remaining after the derivative transaction, providing additional potential equity exposure through future option exercises.

Were Sharon Townson’s Monte Rosa Therapeutics (GLUE) stock sales pre-planned?

Yes. The Form 4 footnotes state that the transactions were effected under a Rule 10b5-1 trading plan adopted on February 27, 2026, indicating the sales were pre-arranged rather than discretionary trades based on short-term market developments.

What type of derivative security did Sharon Townson exercise at Monte Rosa Therapeutics (GLUE)?

She exercised a “Stock Option (Right to Buy)” covering 6,000 underlying shares of Monte Rosa Therapeutics common stock, at a conversion or exercise price of $6.14 per share, as disclosed in the derivative section of the Form 4 filing.